



**3,000 ATTENDEES & EXHIBITORS | 50+ COUNTRIES REPRESENTED | 500+ ORAL PRESENTATIONS
1,200+ POSTER SESSIONS | 2 STATE-OF-THE-ART SPEAKERS**

**THE AMERICAN TRANSPLANT CONGRESS (ATC) 2022 RESUMES IN-PERSON IN BOSTON TO
SHOWCASE LATEST ADVANCES, CUTTING-EDGE RESEARCH FROM WORLD'S LEADING EXPERTS**

[The American Transplant Congress, ATC2022](#) will take place in-person once again from June 4 to June 8, 2022, with a robust program that includes new scientific and clinical information, discussions around care and management, and socioeconomic, ethical and regulatory issues relevant to organ and tissue transplantation. Highlights of this year's program include State-of-the-Art speakers Nancy Ascher, MD, PhD, of the University of California, San Francisco, discussing the U.S.'s role in global transplantation and Martine Rothblatt, PhD, Chairman, CEO and Founder of United Therapeutics Corp., discussing the first xenotransplanted heart.

Congress organizers planned a variety of formats that will encourage the exchange of new scientific and clinical information and support an interchange of opinions on issues relevant to organ and tissue transplantation. Scientific material will be presented through symposia, oral abstracts, concurrent workshops, and poster presentations, as well as small group sessions designed for in-depth exploration of both clinical and basic science topics.

The American Transplant Congress is the Joint Annual Meeting of the [American Society of Transplant Surgeons \(ASTS\)](#) and the [American Society of Transplantation \(AST\)](#). ATC provides a forum for exchange of new scientific and clinical information relevant to solid organ and tissue transplantation and brings together transplant physicians, scientists, nurses, organ procurement personnel, pharmacists, allied health professionals and other transplant professionals. The educational offerings provide attendees the opportunity to learn cutting-edge advances in research and the exchange of ideas and practice in the field of solid organ and tissue transplantation.

Who Should Attend

The American Transplant Congress is designed for physicians, surgeons, scientists, nurses, organ procurement personnel, pharmacists and other transplant professionals who are interested in the clinical and research aspects of solid organ and tissue transplantation. The meeting will provide the most current information in the field of transplant science.

This year, ATC will be returning to an in-person Congress which will take place at the John B. Hynes Convention Center in Boston, MA, USA. In-person attendees have the opportunity to gain access to innovators in the field while having their voice heard through various types of interaction.

In-person Registration includes:

- Invited Symposia
- Plenary & Oral Abstract Sessions
- Sponsored Satellite Symposia
- Meet-the-Expert Sessions
- Poster Abstract Chats
- Sponsor Product Theater Presentations
- In-Person Networking with Attendees
- In-Person Networking with Sponsors
- Live Stream Platform
- ATC OnDemand
- Education Credits (CME, ANCC, ACPE & ABTC)

ATC 2022 also offers a Virtual-Only attendee option for those unable to join in Boston. In-person sessions will be live streamed to the virtual audience in real-time, allowing the virtual audience the opportunity to submit questions to the in-person speakers in real-time.

Virtual Registration includes:

- Invited Symposia
- Plenary & Oral Abstract Sessions
- Sponsored Satellite Symposia
- Live Stream Platform
- ATC OnDemand
- Education Credits (CME, ANCC, ACPE & ABTC)

Real-Time Interactivity

The 2022 program will provide ample opportunities for real-time interactivity through:

- Live In-person Discussions
- Invigorating Q&A Discussions Post-Presentation
- Live Presentations by Abstract Presenters
- Engaging, Unconventional Networking Breaks (In-person Attendees Only)
- Live Symposia

5 Days of Sessions

Congress organizers bring together all facets of research and discovery to include:

- 124 Symposia with Presentations and Question & Answer
- 15 Meet-the-Expert sessions with access to experts in the field (In-person Attendees Only)
- 2 State-of-the-Art lectures from pioneers in the transplant field
- 1 Innovations in Transplantation session on Clinical Xenotransplant Updates

Abstracts Presentation Sessions

This year, the layout is designed with specific time slots on the Scientific Program to engage with abstract presenters:

- **4 Plenary Abstract Sessions** with Presentations and Question & Answer
- **67 Rapid Fire Oral Abstract Sessions** with Presentations and Question & Answer
- **8 Poster Chat Sessions.** Conversation to take place in small groups (In-person Attendees Only)

In addition, ATC2022 features **In-Depth Symposia**, which are 2 and ½ hour sessions designed around a specific topic of interest. These sessions provide in-depth state-of-the-art information focused both on clinical and research areas from various perspectives, allowing attendees to make connections and incorporate the knowledge acquired into their everyday practice.

Special Impact Sessions offer attendees the chance to learn from Industry Innovators on how the transplant industry is transforming daily work lives for tomorrow's advancements. Attendees can expect to leave these sessions armed with cutting-edge information that will pave the way to the future of the industry.

Focus in Transplantation offers a deep dive into presentations on Basic and Translational science. Individual sessions on "Basic: OMICS in Transplantation" and "Translational: Translational Role of Biomarkers in Immune Profiling" will be presented.

For the second year, the **Innovations in Transplantation** session will take place. This year's session titled "[Clinical Xenotransplantation Updates](#)" will review the development of cutting-edge gene editing technology coupled with advances in novel immunosuppression, preclinical models of xenotransplantation in heart, kidney and islet to achieve significant advances. Featured members of the respective teams who performed landmark procedures will briefly discuss their findings followed by a discussion with experts in the field regarding the ethics and practical considerations that will be required as we consider clinical trials in xenotransplantation.

Again, this year, ATC offers a special **Women's Networking Event** that will go beyond the curriculum to discuss strategies to achieve personal and professional success. All In-person attendees are encouraged to attend this event.

This year's abstract sessions include **Plenary Oral Abstract Sessions**, which feature the ATC People's Choice Award Awards, giving attendees the chance to vote on the most impactful plenary abstract presented. In addition, the Congress features rapid Fire Abstract Presentations (five minutes each) with a question-and-answer period.

A new category of **Late-breaking Clinical Trial Abstracts** invites submissions of abstracts describing results of clinical trials in which results become available after the initial abstract deadline and can be presented at the conference. For the first time, ATC has accepted submissions that highlight ongoing trials of importance in transplantation without interim or final results available.

About the American Transplant Congress

[The American Transplant Congress](#) is designed for physicians, surgeons, scientists, nurses, organ procurement personnel, pharmacists and other transplant professionals who are interested in the clinical and research aspects of solid organ and tissue transplantation. The meeting will provide the most current information in the field of transplant science. Early registration with discounted pricing for the meeting ends May 5, 2021. More information is available [HERE](#). To learn more, visit www.atcmeeting.org or connect with ATC on [Twitter](#), [@ATCMeeting](#), [Facebook](#), and [Instagram](#) and [LinkedIn](#).

About the American Society of Transplant Surgeons

The [American Society of Transplant Surgeons](#) (ATS) represents approximately 1,900 professionals dedicated to excellence in transplantation surgery. Our mission is to advance the art and science of transplant surgery through patient care, research, education, and advocacy. To learn more, visit [ASTS.org](#).

About the American Society of Transplantation

The [American Society of Transplantation](#) (AST) represents more than 4,000 transplantation professionals dedicated to advancing the field and improving patient care by promoting research, education, advocacy, and organ donation. The AST's diverse membership includes physicians, surgeons, scientists, nurses, allied health professionals, and administrators. For more information about the AST, please visit [myAST.org](#).

Media Contact:

Julia Brannan-Rauch

julia@mojjocc.com

201-725-7375



ABOUT THE AMERICAN TRANSPLANT CONGRESS (ATC)

What is the American Transplant Congress (ATC)?

The American Transplant Congress is the Joint Annual Meeting of the [American Society of Transplant Surgeons \(ASTS\)](#) and the [American Society of Transplantation \(AST\)](#). ATC provides a forum for exchange of new scientific and clinical information relevant to solid organ and tissue transplantation and brings together transplant physicians, scientists, nurses, organ procurement personnel, pharmacists, allied health professionals and other transplant professionals. The educational offerings provide attendees the opportunity to learn cutting-edge advances in research and exchange of ideas and practice in the field of solid organ and tissue transplantation.

Who should attend ATC2022?

The Congress is designed for physicians, surgeons, scientists, nurses, organ procurement personnel, pharmacists and other transplant professionals interested in solid organ and tissue transplantation.

Is the ATC in-person or virtual?

The leadership of ASTS and AST along with the ATC Program Planning Committee have developed an expansive ***In-person Congress*** experience. The ATC Program Planning Committee is building a robust program that will allow in-person attendees the opportunity to gain access to innovators in the field while having your voice heard through various types of interaction.

This year, ATC will also offer a ***Virtual Only Attendee*** option for those unable to join in Boston. Sessions will be live streamed to the virtual audience in real-time allowing them the opportunity to submit questions in real-time.

[Full Listing of What's Included with In-person and Virtual Only Options](#)

The ATC2022 Program Features:

IMPACT SESSIONS

Learn from industry innovators on how the transplant industry is transforming your daily work lives for tomorrow's advancements. Attendees can expect to leave these sessions armed with cutting-edge information that will pave the way to the future of the industry. Each presentation will close with 3 takeaways on how their topic is impactful to the transplant community.

IN-DEPTH SYMPOSIA

In-Depth Symposia are half day sessions designed around a specific topic of interest. These sessions provide in-depth state-of-the art information focused both on clinical and research areas from various perspectives, allowing attendees to make connections and incorporate the knowledge acquired into their everyday practice.

MEET THE EXPERT

These sessions are designed in an intimate round-table discussion setting — NO formal slide presentations. The purposeful layout is designed to allow interaction and discussion, while creating new connections.

FOCUS IN TRANSPLANTATION

Deep dive into focused presentations on Basic and Translational science. Individual sessions on “Basic: “OMICS in Transplantation” and “Translational: Translational Role of Biomarkers in Immune Profiling” will be presented.

INNOVATIONS IN TRANSPLANTATION

This year’s session titled “[Clinical Xenotransplantation Updates](#)” will review the development of cutting-edge gene editing technology coupled with advances in novel immunosuppression, preclinical models of xenotransplantation in heart, kidney and islet to achieve significant advances. Featured members of the respective teams who performed landmark procedures will briefly discuss their findings followed by a discussion with experts in the field regarding the ethics and practical considerations that will be required as we consider clinical trials in xenotransplantation.

CONTROVERSIES IN TRANSPLANTATION

Come experience top level experts debate controversial topics on “Public Policy: Selflessness or Selfishness: What Philosophy Should Underpin Organ Donor Registration Initiatives?” and “Basic: We Need Car T-Cells to Effectively Desensitize High PRA Patients”

ABSTRACT AND POSTER PRESENTATIONS

Learn about the latest research that is being done around the globe from your fellow attendees presented in a variety of formats. Oral abstracts submitted through the ATC abstract submission are presented orally with time for questions from the audience at the end of each presentation. Poster abstracts presentations will be displayed daily in the exhibit hall for viewing throughout the day

What is the American Society of Transplant Surgeons?

The [American Society of Transplant Surgeons](#) (ASTS) represents approximately 1,900 professionals dedicated to excellence in transplantation surgery. Our mission is to advance the art and science of

transplant surgery through patient care, research, education, and advocacy. To learn more, visit ASTS.org.

What is the American Society of Transplantation?

The American Society of Transplantation (AST) represents more than 4,000 transplantation professionals dedicated to advancing the field and improving patient care by promoting research, education, advocacy, and organ donation. The AST's diverse membership includes physicians, surgeons, scientists, nurses, allied health professionals, and administrators. For more information about the AST, please visit myAST.org.

ATC Media Contact:

Julia Brannan-Rauch

julia@mojjocc.com

201-725-7375



STATE-OF-THE-ART SPEAKER

Nancy Ascher, MD, PhD



University of California San Francisco
Professor of Surgery
Division of Transplant Surgery
Isis Distinguished Professor in Transplantation

PRESENTATION TITLE: United States' Role in Global Transplantation

Paul I. Terasaki State-of-the-Art Lecture

Sponsored by the Terasaki Innovation Center

Sunday, June 5, 2022

11:30 am - 12:00 pm ET

Dr. Nancy Ascher has devoted her career to organ transplantation and transplant research. She is the first woman to have performed a liver transplant and has inspired many women in the medical field, especially in transplantation.

She completed her undergraduate and medical education at the University of Michigan, Ann Arbor; and completed her general surgery residency and clinical transplantation fellowship at the University of Minnesota, where she later joined the faculty and became Clinical Director of the Liver Transplant Program. Dr. Ascher was recruited by the UCSF Department of Surgery and served as the Department Chair for 17 years.

Dr. Ascher is a fellow of the American College of Surgeons. She is a member of numerous other medical societies, including the Transplantation Society and the American Society of Transplant Surgeons, both of which she has served as President. She has also served on the Presidential Task Force on Organ Transplantation, Surgeon General's Task Force on Increasing Donor Organs, and Secretary of Health and Human Services Advisory Committee on Organ Transplantation. Dr. Ascher is currently a member of the WHO Taskforce on Donation and Transplantation of Human Organs and Tissues.



STATE-OF-THE-ART SPEAKER

Martine Rothblatt, PhD



Chairman/CEO/Founder, United Therapeutics Corp

PRESENTATION TITLE: Creating the 1st Life-Saving Xenoheart Transplanted into a Person

Thomas Starzl State-of-the-Art Lecture

Tuesday, June 7, 2022

11:45 am - 12:15 pm ET

Martine Rothblatt is the Chairperson & CEO of United Therapeutics Corporation (UT). She started UT to save her youngest child's life from a rare illness after having previously created SiriusXM satellite radio and other satellite communications systems. She is also responsible for several innovations in aviation and architecture, including the design and piloting of an electric helicopter to Guinness World Records and creating the world's largest zero carbon footprint building. Her company is now saving hundreds of lives a year with medicines for pulmonary hypertension and neuroblastoma, and by restoring otherwise discarded donor lungs to transplantability.

United Therapeutics is also in pre-clinical development of manufactured kidneys, hearts and lungs to be delivered via autonomously flown electric vertical takeoff and landing (eVTOL) systems. Dr. Rothblatt led the efforts to create the first genetically-modified porcine hearts and kidneys transplanted into humans (xenotransplantation), resulting in a lifesaving xeno-heart transplant in January 2022.

Dr. Rothblatt earned her Ph.D. in Medical Ethics from the Royal London College of Medicine and Dentistry after earning JD and MBA degrees from UCLA, which also recently awarded her the UCLA Medal, its highest honor. She is an inventor on several patents and the author of several books, the most recent of which pertain to artificial cognition and cyber-consciousness.



Joint Planning Committee

Executive Committee

Matthew Levine, MD, PhD
University of Pennsylvania
Philadelphia, PA
Chair

Jesse Schold, PhD, M.Stat, M.Ed
Cleveland Clinic Foundation
Cleveland, OH
Chair

Linda Sher, MD
University of Southern California
Los Angeles, CA
Co-Chair

Andrew Adams, MD, PhD
University of Minnesota
Minneapolis, MN
Co-Chair

Roberto Hernandez, MD
University of Rochester
Rochester, NY
Co-Chair Elect

John Friedewald, MD
Northwestern University
Chicago, IL
Co-Chair Elect

Planning Committee

Robert Montgomery, MD, FACs, PhD
NYU Langone Transplant Institute
New York, NY

Daniela Ladner MD, MPH
Northwestern University
Chicago, IL

Parsia Vagefi, MD
University of Texas Southwestern
Dallas, TX

Talia Baker, MD
University of Utah School of Medicine
Salt Lake City, UT

Amy Friedman, MD
LiveOnNY
New York, NY

Samantha Halpern, MSN, CRNP
Washington University School of Medicine
St. Louis, MO

Gregory McKenna, MD
Baylor Scott & White Health
Dallas, TX

Satish Nadig, MD, PhD
Northwestern University
Chicago, IL

Shunji Nagai, MD, PhD
Henry Ford Hospital
Detroit, MI

Raymond Razonable, MD
Mayo Clinic College of Medicine & Science
Rochester, MN

Jordan Pober, MD, PhD
Yale University School of Medicine
New Haven, CT

Vikas Dharnidharka, MD, MPH
Washington University St. Louis
St. Louis, MO

Nicole Turgeon, MD
Dell Seton Medical Center at the University of Texas
Austin, TX

Christina Doligalski, PharmD
University of North Carolina
Chapel Hill, NC

Darshana Dadhania, MD, MS, FAST
New York Presbyterian/Weill Cornell Medical Center
New York, NY

Elizabeth Verna, MD, MS
Columbia University
Hartdale, NY

Patricia Campbell, MBChB
University of Alberta
Edmonton, AB

Josef Stehlik, MD
University of Utah School of Medicine
Salt Lake City, UT